Biomarker Working Group To Explore Development Of Guidance
Executive Summary
An FDA working group will be formed by year-end to consider the development of a guidance on biomarkers
You may also be interested in...
FDA Disease Models Will Focus On Areas With Poor R&D Track Records
FDA's disease state modeling efforts may focus on therapeutic areas which traditionally have suboptimal drug development, Office of Clinical Pharmacology & Biopharmaceutics Director Larry Lesko said
FDA Disease Models Will Focus On Areas With Poor R&D Track Records
FDA's disease state modeling efforts may focus on therapeutic areas which traditionally have suboptimal drug development, Office of Clinical Pharmacology & Biopharmaceutics Director Larry Lesko said
Pharmacometrics Can Guide Further Trials, Minimize Risks – FDA Analysis
Pharmacometric analysis can be used to refine the design of further studies following failed clinical trials, according to an analysis by reviewers in FDA's Office of Clinical Pharmacology & Biopharmaceutics